



Translational Studies of Obesity-Associated Hepatocellular Cancer

Guest Editors:

Prof. Dr. Nathan A. Berger

Department of Medicine,
Biochemistry, Oncology, Genetics
& Genome Sciences, Case
Western Reserve University
School of Medicine, Cleveland,
OH 44106, USA

Dr. J. Mark Brown

Department of Cardiovascular &
Metabolic Sciences, Center for
Microbiome & Human Health,
Cleveland Clinic Lerner Research
Institute, Cleveland, Ohio 44195,
USA

Deadline for manuscript
submissions:

closed (31 March 2021)

Message from the Guest Editors

Dear Colleagues,

Hepatocellular Carcinoma (HCC) is the most prevalent form of primary liver cancer, and is among the leading causes of cancer-related deaths around the world. With a 5 year survival rate of less than 15%, HCC is etiologically associated with viral hepatitis, alcohol excess, other hepatotoxins, and metabolic disorders including obesity and type 2 diabetes mellitus (T2DM). While hepatitis and hepatotoxins remain significant causes of HCC, its increasing incidence in many countries is associated with expansion of the obesity pandemic. HCC has been designated an obesity-associated cancer, particularly in men. This Special Issue of *Cancers* will focus on translational aspects of obesity-associated HCC across the spectrum, from mechanisms and prevention to diagnosis and therapeutics. Articles are invited that study obesity-associated metabolic, immunologic, inflammatory, pathologic, microbiologic, genetic, and molecular alterations that impact obesity-associated HCC as well as their therapeutic implications.

Prof. Dr. Nathan A. Berger

Dr. J. Mark Brown

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)